TABLE 2.

Oligonucleotide primers used in this study

PrimerSequencea
F5′-TAGAAAAGTATATTTGTATACCCT-3′
R5′-CGCCACTAACTTGAGGCTTTA-3′
R15′-AATTTTTGGCTAATTATATCTTAATTT-3′
CHLF5′-TGCTCGGCGGTGTTCCTTT-3′
CHLR5′-GCGCCCTTTAGTTCCTAAAG-3′
RF5′-ATAGGATCCATGAACTCAAATAGAACACCA-3′ (BamHI)
RR5′-TTTTAAGCTTTGGAGCTATTGATT-3′ (HindIII)
GSF5′-CTAAATGGAATCAATAGCTCC-3′
GSR15′-GCACAACACCTAAAGCTAAAA-3′
GSR25′-TAAAAATTGTAATATTTATTACAG-3′
GSR35′-ATTGTAATATTTATTACAGAAATT-3′
GSR45′-GAAATTTTTGGCTAATTATAT-3′
AF5′-AACCTCAAGTTAGCGGCGTA-3′
AR5′-AATCCTTGCTTGCATTTTCG-3′
PF5′-AAAAGGATCCTAAATGGAATCAATAGCTCC-3′ (BamHI)
PR5′-ATCTCGGTATGATCTAGATCA-3′ (XbaI)
  • a Underlining indicates restriction sites. The names of the restriction sites are listed in parentheses following the sequences.